

ALEXION PHARMACEUTICALS INC  
Form SC 13G  
March 06, 2006

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**Information Statement Pursuant to Rules 13d-1 and 13d-2**

**Under the Securities Exchange Act of 1934**

**(Amendment No. \_\_)\***

ALEXION PHARMACEUTICALS, INC.

---

**(Name of Issuer)**

Common, \$.0001 par value per share

---

**(Title of Class of Securities)**

015351 10 9

---

**(CUSIP Number)**

February 24, 2006

---

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form SC 13G

“ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 015351 10 9

1. NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Brookside Capital Partners Fund, L.P.

EIN No.: 04-3313066

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) ..

(b) ..

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

NUMBER OF 5. SOLE VOTING POWER

SHARES 1,921,500

BENEFICIALLY 6. SHARED VOTING POWER

0

OWNED BY 7. SOLE DISPOSITIVE POWER

EACH 1,921,500

REPORTING 8. SHARED DISPOSITIVE POWER

PERSON 0

WITH

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,921,500

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

..

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.2%

12. TYPE OF REPORTING PERSON\*

PN

Item 1 (a). **Name of Issuer**

The name of the issuer to which this filing on Schedule 13G relates is Alexion Pharmaceuticals, Inc. (the Company ).

Item 1 (b). **Address of Issuer's Principal Executive Offices**

The principal executive offices of the Company are located at 352 Knotter Drive, Cheshire, Connecticut, 06410.

Item 2 (a). **Name of Person Filing**

This Statement is being filed on behalf of Brookside Capital Partners Fund, L.P., a Delaware limited partnership (the Brookside Fund ). Brookside Capital Investors, L.P., a Delaware limited partnership (Brookside Investors ) is the sole general partner of the Brookside Fund. Brookside Capital Management, LLC, a Delaware limited liability company (Brookside Management ), is the sole general partner of Brookside Investors. Mr. Domenic J. Ferrante is the sole managing member of Brookside Management.

Item 2 (b). **Address of Principal Business Office or, if none, Residence**

The principal business address of each of the Brookside Fund, Brookside Investors, Brookside Management and Mr. Ferrante is 111 Huntington Avenue, Boston, Massachusetts 02199.

Item 2 (c). **Citizenship**

Each of the Brookside Fund, Brookside Investors and Brookside Management is organized under the laws of the State of Delaware. Mr. Ferrante is a citizen of the United States.

Item 2 (d). **Title of Class of Securities**

The class of equity securities of the Company to which this filing on Schedule 13G relates is Common Stock, \$.0001 Par Value per share ( Common Stock ).

Item 2 (e). **CUSIP Number**

The CUSIP number of the Company's Common Stock is 015851 10 9.

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable.

- (a) .. Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) .. Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
- (c) .. Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) .. Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) .. An investment adviser in accordance with §13d-1(b)(1)(ii)(E).

- (f) .. An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
  - (g) .. A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
  - (h) .. A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
  - (i) .. A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
  - (j) .. Group, in accordance with §240.13d-1(b)(1)(ii)(J).
- x **If this statement is filed pursuant to §240.13d-1(c), check this box.**

**Item 4. Ownership**

**Item 4 (a). Amount beneficially owned**

As of the close of business on February 24, 2006 and March 3, 2006, the Brookside Fund owned 1,613,500 and 1,921,500 shares of Common Stock, respectively. The Brookside Fund acts by and through its general partner, Brookside Investors. Brookside Investors acts by and through its general partner, Brookside Management. Mr. Domenic J. Ferrante is the managing member of Brookside Management and thus is the controlling person of Brookside Management. No person other than the respective owner referred to herein of shares of Common Stock is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of such shares of Common Stock.

**Item 4 (b). Percent of class**

As of the close of business on February 24, 2006 and March 3, 2006, the Brookside Fund was the beneficial owner of 5.2% and 6.2% of the Common Stock of the Company, respectively. The aggregate percentage of Common Stock reported owned by the Brookside Fund is based upon 30,914,583 shares of Common Stock outstanding, which is the total number of shares of Common Stock outstanding as of November 30, 2005, based on representations made in the Company's Form 10-Q for the quarter ending October 31, 2005 filed with the Securities and Exchange Commission on December 6, 2005.

**Item 4 (c). Number of shares as to which such person has:**

- (i) sole power to vote or to direct the vote:

1,921,500

- (ii) shared power to vote or to direct the vote:

0

- (iii) sole power to dispose or to direct the disposition of:

1,921,500

- (iv) shared power to dispose or to direct the disposition of:

0

**Item 5. Ownership of Five Percent or Less of a Class**

Not Applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not Applicable.

**Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable.

**Item 9. Notice of Dissolution of Group**

Not Applicable.

Item 10. **Certification**

By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Dated: March 6, 2006

BROOKSIDE CAPITAL PARTNERS FUND, L.P.

By: /s/ Domenic J. Ferrante

Name: Domenic J. Ferrante

Title: Managing Director